Seven drugs join TGA review list

The TGA accepted seven innovative medicines for review in June, including Novartis’ long-lost lung cancer treatment Tabrecta initially filed three years ago.

Tabrecta was filed with the TGA under orphan status in June 2022 for the treatment of non-small cell lung cancer with genetic MET alterations but never made it over the line, disappearing from the regulator’s review list in the following year.

According to an update to the TGA’s review list, the MET inhibitor is currently under review for adults with NSCLC with a MET exon 14 skipping mutation that has spread throughout the body.